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Abstract: We expressed the M2 gene in prokaryotic cells using the pAED4 expression vector system to produce native
and purified M2 protein as a candidate for universal recombinant vaccine against influenza A subtypes. The open reading
frame (ORF) of avian influenza A/chicken/Iran/101/1998 (H9N2) M2 gene was amplified by 2-step RT-PCR using specific
primers and pfu DNA polymerase. pAED4 was used as expression vector, purified PCR product digested by Nde I and
EcoR I restriction enzymes was ligated to the same digested site in the vector using T4 ligase to form pAED4-M2.
The cloned M2 gene was confirmed by PCR and restriction enzymes pattern. M2 polypeptide was produced through the
expression of this recombinant expression vector (pAED4+M2) in Escherichia coli BL21 (DE3) strain. The expressed M2
polypeptide was analyzed on SDS-PAGE and confirmed by western blotting assay. The level of 100% homology between
the N-terminal domain of H5 and H9 isolates was considerable. It seems that recombinant vaccine based on Iranian
isolate A/chicken/Iran/101/1998(H9N2) M2 protein might cover all H5 and H9 circulating in Iran and neighboring
regions significantly. Further research will be needed to evaluate the immunity of the expressed M2 protein in the lab
animal model to check the native conformational structure of this expressed protein by challenging with other influenza
isolates.
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Introduction
Yearly development of influenza vaccines that are
antigenically matched to circulating strains poses
extraordinary challenges. A rapidly developing
pandemic would shorten the time for strain
identification and vaccine preparation; meanwhile,

antigenic changes would continue. Moreover, the
need to immunize an entirely naive population would
exacerbate problems with vaccine production and
supply. Vaccines based on conserved antigens would
not require prediction of which strains would
circulate during an approaching season and could
avoid hurried manufacturing in response to
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outbreaks. Test vaccination with DNA constructs that
express conserved influenza A nucleoprotein (NP) or
NP plus matrix (M) induced antibody and T-cell
responses and protected against heterosubtypic
viruses (1,2). Despite the virulence and rapid kinetics
of challenge infection, DNA vaccination with NP and
M achieved limited protection against an H5N1 virus
strain isolated from the 1997 human outbreak in
Hong Kong (3).
The gene segment 7 of avian influenza A encodes
2 proteins, both highly conserved: M1, the capside
protein, and M2, an ion channel protein. M2 contains
a small ectodomain (M2e), which makes it a target for
antibody-based immunity. The ability of anti-M2
monoclonal antibody (MAb) to reduce viral
replication (4) implicates M2, in particular M2e, as a
vaccine target. M2 vaccine candidates that have been
explored include peptide-carrier conjugates (5),
baculovirus-expressed M2 (6), fusion proteins (7,8),
multiple antigenic peptides (9), and M DNA
constructs that potentially express M2 (10,11).
Therefore, in this study we expressed the M2 gene in
prokaryotic cells using the pAED4 expression vector
system to produce native and purified M2 protein as
a candidate for universal recombinant vaccine against
influenza A subtypes.
Materials and methods
Viral isolate and viral RNA preparation: Avian
influenza A/chicken/Iran/101/1998 (H9N2) used as a
vaccinal seed in Marand branch of Iran’s Razi
Institute was grown in primary SPF chicken embryo
fibroblast (CEF). Influenza virus infected cells were
collected after 18 h by centrifugation at 3000 × g for 10
min following cell culture trypsinization.
Total RNA was extracted by the guanidinium
isothiocyanate method using RNX-Plus™ (Tehran,
Cinagen, Iran) solution. Then the extracted total RNA
dissolved in 20 μL of RNase-free water (DEPC water).
Primer design: To clone full-length spliced M2
mRNA in cell culture, 2 gene-specific primers (M2U
and M2L) were designed, and the gene specific
sequences were selected by comparison and
alignment of M2 gene sequences retrieved from the
GenBank database by DNAMAN (version 4.13) and
Oligo (version 5) software.
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The
M2U
(Forward)
primer:
5′GGAATTCCATATGAGTCTTCTAACCGAG 3′
contained an Nde I restriction site before the start
codon, and the M2L (Reverse) primer:
5′GGAATTCCTTACTCCAGCTCTATGTTG
3′
contained an EcoR I restriction site after the stop
codon.
cDNA synthesis and RT-PCR: After total RNA
extraction, the cDNA synthesis was performed by
AMV first strand cDNA synthesis kit (Mannheim,
Roche, Germany) using random hexamer oligoes
according to the manufacturer’s protocol. Then the
cDNA was amplified using specific primers (M2U and
M2L) for the 310 bp fragment of the spliced M2 gene
containing restriction site sequences.
A polymerase chain reaction (PCR) was carried
out in a 50 μL mixture containing 5 μL of 10× reaction
buffer with MgSO4, 4 μL of mixed dNTPs (2.5 mM
each), 1 μL of each specific primer (10 pmol each), 0.5
μL of pfu DNA polymerase (2.5 u/μL) (Mannheim,
Roche, Germany), 3 μL of cDNA template, and 35.5
μL of DEPC water. The PCR program was 95 °C for 3
min, 5 cycles of 95 °C for 1 min, 54 °C for 1 min, and
72 °C for 1 min, then 30 cycles of 95 °C for 1 min, 56
°C for 1 min, and 72 °C for 1 min, followed by 72 °C
for 10 min. At the end the PCR products were
analyzed by 1.5% agarose electrophoresis.
Construction of expression vector: The PCR
products were run on 1% agarose gel electrophoresis
and the distinct band was purified using a PCR
product purification kit (Mannheim, Roche,
Germany) according to the manufacturer’s protocol
from gel for double digestion. pAED4 was used as
expression vector, and purified PCR product digested
by Nde I and EcoR I (Fermentas, Vilnius, Lithuania)
restriction enzymes was ligated to the same digested
site in the vector using T4 ligase (Fermentas, Vilnius,
Lithuania) to form pAED4-M2
Expression of recombinant M2 protein: pAED4M2 was transformed into Escherichia coli BL21 (DE3)
competent cells. The cells were cultured in LB broth
containing 100 μg/mL ampicillin and incubated at 37
°C on a shaker incubator until the optical density at
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600 nm reached 0.6. Then 0.5 mM of isopropythio βD-galactosidase (IPTG) was added to the medium to
induce M2 gene expression. Samples were collected
before (zero time) and after (1, 2, and 4 h) induction
of expression for SDS-PAGE analysis.
SDS-PAGE
and
immunoblotting:
For
characterization of expressed M2 protein, samples
were lysed by addition of protein sample buffer and
heated at 100 °C for 5-10 min. Then extracts were
electrophoresed in SDS-17.5% polyacrylamide gel and
transferred into a polyvinylidene fluoride (PVDF)
membrane (Roch, Germany). After blocking with 3%
BSA, the immunoblotting was carried out with rabbit
anti-influenza A virus M2 protein polyclonal Ab
(abcam, Cambridge, UK) and mouse anti-rabbit IgG
HRP (Santa Cruz, California, USA) according to the
manufacturer’s protocol.
Results
Analysis of the M2 gene sequences: PCR was able
to amplify the desirable fragment (294 bp) of the open
reading frame (ORF) of A/chicken/Iran/101/1998
(H9N2) spliced M2 gene (Figure 1). The maximum
M2 gene homology was between the Iranian isolate
and H9 and H5 isolates from Dubai, Pakistan, and
Hong Kong. The nucleotide sequence of the Iranian
isolate M2 gene was just 2% divergent from the most
closely related viruses in GenBank. The nucleotides
sequence of this gene was deposited in GenBank as
accession number EU477375.
Gene analysis in vector: The desirable fragment of
the M2 gene was cloned into the multiple cloning site
region of the pAED4 expression vector. Identity of the
cloned gene was confirmed by PCR and restriction
analysis (Figure 2).
Gene expression and immunoblotting: A band
with approximately 15 KDa of M2 protein was
observed 1, 2, and 4 h after induction while this band
was not seen in the negative control or positive
control (Figure 3). The desirable band was confirmed
by western blotting analysis using polyclonal M2
protein antibody (Figure 4).

Figure 1. Analysis of PCR product on 1.2% agarose gel, lane 1,
contains a 100-bp DNA ladder; lanes 2 and 3 contain
positive samples in which the upper bands are segment
7 (26-1027 nt) and the lower bands are the M2 gene
(ORF); lane 4 contains a negative control; lane 5
contains a 1 kb DNA ladder.

Discussion
The M2 protein is abundantly expressed at the
surface of virus infected cells, but in comparison with
the unstable hemagglutinin (HA) and neuraminidase
(NA) glycoproteins, the M2 protein is a minor
component of virions. It has essential role in the life
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Figure 3. SDS-PAGE analysis of E. coli BL21 (DE3) stained by
silver nitrate and showing the expression of the M2
gene. Lane M: negative control (bacteria without
plasmid); lane 0: bacteria with plasmid before
induction; lane 1, 2, 4: bacteria with expression plasmid
1, 2, 4 h after induction, respectively; lane M: low
molecular size marker (Fermentas).

Figure 2. PCR and restriction enzyme analysis of the constructed
pAED4+M2. Lane 1, 7: size marker 1Kb (fermentas);
lane 2: pAED4 with insert (pAED4+M2); lane 3:
pAED4+M2 product partially digested with Nde I and
EcoR I; lane 4: pAED4+M2 product completely
digested with Nde I and EcoR I; lane 5: PCR analysis of
pAED4+M2 using specific primers; lane 6: negative
control.

cycle of influenza virus replication. The current
strategy for developing vaccine has been focused on
inducing neutralizing antibody against HA or NA
glycoproteins, but it was indicated that these 2
glycoproteins show great antigenic diversity among
influenza A subtypes (12).
Extracellular M2 protein can be suggested as a
target of host humoral immunity induction.
Therefore, it can produce antibody as an inhibitory
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antibody against influenza A subtypes by blocking the
extracellular domain of M2 homotetramer protein.
This way of blocking can inhibit viral fusion and
budding of viral particles after viral host cell entry.
This inhibition of viral replication is more efficient
than the amantadine and remantadine antiviral drugs,
which block the viral replication by blocking the
transmembrane domain of M2 ion channel protein on
virus particles and apical surface of virus-infected
cells. Previous research has shown that an anti-M2
protein antibody can restrict virus growth in vitro (4)
and partially protect passively immunized mice from
infection with influenza virus (13).
Our sequence alignment showed that the M2
protein from avian influenza A virus strain is
conserved among all isolates from different hosts and
areas, and the N-terminal domain of the M2 protein,
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A/Ann Arbor/6/60 [H2N2]) reacted well with M2
protein expressed in this study. This cross-reactivity
in addition to extraplotting sequence alignment could
be a good indication that immunity against M2
protein of H9N2 might cover other influenza isolates,
particularly H5N1.
We expressed M2 protein as a cytoplasmic
inclusion body in the native and inactive form,
western blotting or ELISA test can change the
protein’s conformational structure to linear form, and
consequently can change the epitopes. Therefore, it
might not be a good representative of native epitopes
in influenza infected host cells.
Further research will be needed to evaluate the
immunity of the expressed M2 protein in the lab
animal model to check the native conformational
structure of this expressed protein by challenging with
other influenza isolates.

Figure 4. Western blot analysis of expressed M2 protein on
PVDF membrane using rabbit anti-influenza A virus
M2 protein polyclonal Ab (abcam, UK) and mouse
anti-rabbit IgG HRP (Santa Cruz, California, USA).
Lane 1, 2: positive reaction; lane 3: negative control.

which is the immunogenic portion, is highly
conserved among H9 and H5 isolates deposited in
GenBank.
In the present study, we used pAED4 expression
vector to produce M2 protein in a native form.
Western blotting assay with M2 protein polyclonal
antibody induced by H2N2 human origin (strain

We cloned, sequenced, and expressed
A/chicken/Iran/101/1998 (H9N2) in prokaryotic cells
using the pAED4 expression system and the expressed
M2 protein was confirmed by SDS-PAGE and western
blotting assay. It seems that the recombinant vaccine
based on Iranian isolate M2 protein might cover all
H5 and H9 circulating in Iran and neighboring
regions significantly.
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